Spain, Lavinia <br/><br/>
Management of toxicities of immune checkpoint inhibitors.  [electronic resource] 

 -  Cancer treatment reviews  Mar 2016 
 - 51-60 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1532-1967 
<br/><br/><label>Standard No.: </label>10.1016/j.ctrv.2016.02.001  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adrenal Cortex Hormones--therapeutic use<br/>Antibodies, Monoclonal--adverse effects<br/>Antibodies, Monoclonal, Humanized--adverse effects<br/>Antilymphocyte Serum--therapeutic use<br/>Antineoplastic Agents--adverse effects<br/>CTLA-4 Antigen--antagonists & inhibitors<br/>Carcinoma, Renal Cell--drug therapy<br/>Chemical and Drug Induced Liver Injury--drug therapy<br/>Colitis--chemically induced<br/>Cyclosporine--therapeutic use<br/>Diarrhea--chemically induced<br/>Drug Eruptions--drug therapy<br/>Humans<br/>Immunosuppressive Agents--therapeutic use<br/>Infliximab--therapeutic use<br/>Ipilimumab<br/>Kidney Neoplasms--drug therapy<br/>Lung Neoplasms--drug therapy<br/>Melanoma--drug therapy<br/>Mycophenolic Acid--analogs & derivatives<br/>Neoplasms--drug therapy<br/>Nivolumab<br/>Pituitary Diseases--chemically induced<br/>Programmed Cell Death 1 Receptor--antagonists & inhibitors<br/>Skin Neoplasms--drug therapy<br/>Tacrolimus--therapeutic use<br/>Thyroiditis--chemically induced